Oncolytics Biotech Advances Breast Cancer Trial with FDA Support
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech (NASDAQ:ONCY) received positive feedback from the FDA for its planned trial of pelareorep in HR+/HER2- metastatic breast cancer. The FDA supports progression-free survival as the primary endpoint and overall survival as a key secondary endpoint.
June 27, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncolytics Biotech received FDA support for its pelareorep trial in HR+/HER2- metastatic breast cancer, which is a significant regulatory milestone.
The FDA's support for the trial is a significant regulatory milestone that could accelerate the development and potential approval of pelareorep, positively impacting Oncolytics Biotech's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100